Report Tools

OTC Pharmaceuticals in Singapore

Published: August 2013 · Publisher: MarketLine
OTC Pharmaceuticals in Singapore industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages38
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6823
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

OTC Pharmaceuticals in Singapore industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Singapore otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.

*The Singaporean OTC pharmaceuticals market had total revenues of $515.0m in 2012, representing a compound annual growth rate (CAGR) of 5.6% between 2008 and 2012.

*The traditional medicines segment was the market's most lucrative in 2012, with total revenues of $252.4m, equivalent to 49% of the market's overall value.

*The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $633.2m by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Singapore

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Singapore

Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Singapore otc pharmaceuticals market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Singapore economy

Key Questions Answered

What was the size of the Singapore otc pharmaceuticals market by value in 2012?

What will be the size of the Singapore otc pharmaceuticals market in 2017?

What factors are affecting the strength of competition in the Singapore otc pharmaceuticals market?

How has the market performed over the last five years?

Who are the top competitiors in Singapore's otc pharmaceuticals market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, Eu Yan Sang International Ltd, GlaxoSmithKline Plc and Johnson & Johnson
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market share 11
Market distribution 12
Market Outlook 13
Market value forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
Eu Yan Sang International Ltd 24
GlaxoSmithKline Plc 27
Johnson & Johnson 31
Macroeconomic Indicators 34
Country Data 34
Appendix 36
Methodology 36
Industry associations 37
Related research 37

LIST OF TABLES
Table 1: Singapore OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Singapore OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Singapore OTC pharmaceuticals market geography segmentation: $ million, 2012 10
Table 4: Singapore OTC pharmaceuticals market share: % share, by value, 2012 11
Table 5: Singapore OTC pharmaceuticals market distribution: % share, by value, 2012 12
Table 6: Singapore OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Table 7: Bayer AG: key facts 20
Table 8: Bayer AG: key financials ($) 21
Table 9: Bayer AG: key financials (€) 21
Table 10: Bayer AG: key financial ratios 22
Table 11: Eu Yan Sang International Ltd: key facts 24
Table 12: Eu Yan Sang International Ltd: key financials ($) 25
Table 13: Eu Yan Sang International Ltd: key financials (Si$) 25
Table 14: Eu Yan Sang International Ltd: key financial ratios 25
Table 15: GlaxoSmithKline Plc: key facts 27
Table 16: GlaxoSmithKline Plc: key financials ($) 28
Table 17: GlaxoSmithKline Plc: key financials (£) 29
Table 18: GlaxoSmithKline Plc: key financial ratios 29
Table 19: Johnson & Johnson: key facts 31
Table 20: Johnson & Johnson: key financials ($) 32
Table 21: Johnson & Johnson: key financial ratios 32
Table 22: Singapore size of population (million), 2008–12 34
Table 23: Singapore gdp (constant 2000 prices, $ billion), 2008–12 34
Table 24: Singapore gdp (current prices, $ billion), 2008–12 34
Table 25: Singapore inflation, 2008–12 35
Table 26: Singapore consumer price index (absolute), 2008–12 35
Table 27: Singapore exchange rate, 2008–12 35

LIST OF FIGURES
Figure 1: Singapore OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Singapore OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Singapore OTC pharmaceuticals market geography segmentation: % share, by value, 2012 10
Figure 4: Singapore OTC pharmaceuticals market share: % share, by value, 2012 11
Figure 5: Singapore OTC pharmaceuticals market distribution: % share, by value, 2012 12
Figure 6: Singapore OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Singapore, 2012 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Singapore, 2012 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Singapore, 2012 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Singapore, 2012 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Singapore, 2012 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Singapore, 2012 19
Figure 13: Bayer AG: revenues & profitability 22
Figure 14: Bayer AG: assets & liabilities 23
Figure 15: Eu Yan Sang International Ltd: revenues & profitability 26
Figure 16: Eu Yan Sang International Ltd: assets & liabilities 26
Figure 17: GlaxoSmithKline Plc: revenues & profitability 29
Figure 18: GlaxoSmithKline Plc: assets & liabilities 30
Figure 19: Johnson & Johnson: revenues & profitability 32
Figure 20: Johnson & Johnson: assets & liabilities 33
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.